Early Infliximab Clearance Predicts Remission in Children with Crohn's Disease
Aaron Chung1, Matthew Carroll1, Patricia Almeida1
1Division of Pediatric Gastroenterology, Faculty of Medicine, University of Alberta, Edmonton, Canada.
Digestive Diseases and Sciences
|December 23, 2022
Summary
Infliximab clearance predicts remission in pediatric Crohn's disease patients. Early monitoring of infliximab clearance can guide treatment adjustments for better outcomes.
Area of Science:
- Pediatric Gastroenterology
- Pharmacokinetics
- Inflammatory Bowel Disease
Background:
- Children with Crohn's disease exhibit lower response rates and higher infliximab clearance compared to adults.
- Weight-based dosing in pediatric Crohn's disease may not optimize infliximab levels or outcomes.
Purpose of the Study:
- To investigate infliximab clearance as a predictor of treatment outcomes in pediatric Crohn's disease.
- To establish early predictors of remission and response to infliximab therapy in children.
Main Methods:
- A retrospective single-center study analyzed data from 85 pediatric Crohn's disease patients.
- A population pharmacokinetic model was developed to calculate individual infliximab clearance.
- Regression and ROC analyses assessed early infliximab clearance as a predictor of remission.
Main Results:
- Early infliximab clearance was the sole significant predictor of remission.
- Increased infliximab clearance was associated with higher CRP and weight, and lower albumin.
- A 0.1 L/day increase in clearance predicted remission (OR 0.179-0.426) with moderate accuracy (AUC 0.682-0.738).
Conclusions:
- Early infliximab clearance is a strong indicator of remission in pediatric Crohn's disease.
- Infliximab clearance may serve as a marker for proactive therapeutic drug monitoring.
- Monitoring infliximab clearance can guide early treatment optimization for improved long-term outcomes.
Keywords:
BiologicsBiomarkersCrohn'sIBDInfliximabPediatricsPharmacokineticsTherapeutic drug monitoringMore Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
210
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
241
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
241
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
01:30Inflammatory Bowel Disease II: Crohn's Disease
337
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
337
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:29Drugs for Treatment of Ulcerative Colitis in IBD
218
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
218